Fmoc-(Hmb)Gly-OH

Fmoc-(Hmb)Gly-OH is an Fmoc-protected glycine derivative bearing a chiral Hmb (2-hydroxy-4-methylbenzyl) ester on the amino acid side-chain, presented as a free carboxylic acid for peptide coupling and downstream functionalization. The molecule combines an N-Fmoc carbamate with a benzylic ester motif that can be selectively removed under hydrogenolysis or acid conditions depending on the Hmb strategy, while the glycine backbone retains the stereochemical context required for controlled incorporation into peptide sequences. The aromatic Hmb group increases hydrophobic character and provides a handle for orthogonal protection schemes, whereas the carboxylic acid enables standard amide bond formation to build peptide chains. The overall reactivity profile supports protected amino acid synthesis workflows and provides a chiral amino acid intermediate suitable for stereochemically defined peptide construction and subsequent derivatization.

1. Peptide Synthesis

Fmoc-(Hmb)Gly-OH as an Fmoc-protected amino acid is designed for solid-phase peptide synthesis and compatible with coupling chemistries that activate the free carboxylic acid while preserving the N-Fmoc group. The presence of the Hmb ester on the side-chain introduces an additional protection element that can be removed orthogonally to the Fmoc group, enabling controlled generation of a functionalized glycine-derived residue during peptide assembly or after chain elongation. The chiral benzylic stereocenter associated with the Hmb group supports stereodefined residue incorporation, which can be important for conformational bias and for maintaining defined chemical identity across synthesis steps. The resulting peptide building block supports preparation of glycine-containing peptides, peptidomimetics, and sequence variants where side-chain deprotection timing is a key design parameter.

2. Protected Amino Acid Chemistry

Fmoc-(Hmb)Gly-OH functions as a protected amino acid derivative for orthogonal protection planning in synthetic organic chemistry, pairing an N-Fmoc carbamate with an Hmb ester that can be selectively cleaved without disrupting the peptide-ready carboxylic acid during handling. The free acid form facilitates incorporation into protected amino acid libraries and enables conversion into activated derivatives for coupling, while the Hmb group provides a stereochemically informative protecting handle for side-chain modification. The benzylic aromatic ester motif can undergo controlled deprotection to reveal a reactive hydroxyl-bearing functionality or to enable downstream transformations that depend on the timing of Hmb removal. The compound therefore serves as a practical intermediate for protected amino acid synthesis, amino acid derivatization, and stepwise construction of chemically defined building blocks used in peptide and peptidomimetic workflows.

3. Peptidomimetics And SAR Studies

Fmoc-(Hmb)Gly-OH can be employed in peptidomimetic construction where glycine analog residues bearing protected functional groups are incorporated to probe structure-activity relationship hypotheses. The combination of the Fmoc-protected amine and the Hmb-protected side-chain provides a controlled platform for generating analogs with defined stereochemistry and side-chain presentation after selective deprotection. The aromatic Hmb group can influence local polarity and steric environment in assembled scaffolds, supporting systematic variation of residue properties during SAR studies. Downstream deprotection and functional group unveiling from the Hmb motif can enable generation of analogs for binding studies, receptor interaction mapping, or conformational analysis using amino acid chemistry-compatible synthetic routes.

4. Chemical Biology Bioconjugation

Fmoc-(Hmb)Gly-OH supports chemical biology workflows that require peptide or peptide-like conjugates with defined attachment points and protected functional groups. The Fmoc handle enables incorporation into peptide sequences that can later be used for site-selective conjugation, while the Hmb-protected side-chain can be unmasked to generate a reactive hydroxyl-bearing functionality that participates in subsequent coupling or derivatization steps. The stereochemically defined Hmb-bearing glycine residue can contribute to controlled conjugate geometry, which is relevant for maintaining consistent chemical identity across labeling batches. The compound can therefore serve as an intermediate for biomolecule modification strategies, including preparation of labeled peptides, linker-bearing constructs, and conjugation-ready building blocks used in biochemical research.

5. Pharmaceutical Manufacturing Intermediates

Fmoc-(Hmb)Gly-OH is suitable for process chemistry and pharmaceutical intermediate preparation where reproducible protected amino acid handling and orthogonal deprotection logic are required for scalable peptide synthesis. The free carboxylic acid and N-Fmoc protection enable standard peptide coupling operations while maintaining stability during intermediate isolation, and the Hmb ester provides a side-chain protection element that can be removed under controlled conditions aligned with manufacturing process design. The chiral nature of the Hmb-bearing residue supports consistent stereochemical outcomes across production lots, which is a key consideration for downstream API-related peptide intermediates and analytical reference material generation. The compound can be integrated into fine chemical synthesis routes that produce protected peptide fragments, defined peptidomimetic intermediates, and subsequent derivatives used in industrial chemical manufacturing pipelines.

1. Quantitative Analysis of Ligands Effects on Bioefficacy of Nanoemulsion encapsulating Depigmenting Active

2. An interdomain binding site on HIV-1 Nef interacts with PACS-1 and PACS-2 on endosomes to down-regulate MHC-I

3. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats

4. Immune responses to peptides containing homocitrulline or citrulline in the DR4-transgenic mouse model of rheumatoid arthritis

5. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment